Neuberger Berman Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$246M Buy
551,522
+5,625
+1% +$2.62M 0.19% 114
2025
Q4
$247M Buy
545,897
+18,406
+3% +$7.93M 0.18% 118
2025
Q3
$207M Buy
527,491
+68,341
+15% +$28.6M 0.15% 149
2025
Q2
$204M Buy
459,150
+16,522
+4% +$7.61M 0.16% 150
2025
Q1
$215M Buy
442,628
+8,317
+2% +$3.88M 0.18% 138
2024
Q4
$175M Buy
434,311
+5,173
+1% +$2.4M 0.14% 177
2024
Q3
$200M Buy
429,138
+1,650
+0.4% +$793K 0.16% 168
2024
Q2
$200M Buy
427,488
+13,438
+3% +$5.83M 0.16% 150
2024
Q1
$173M Buy
414,050
+18,270
+5% +$7.72M 0.14% 185
2023
Q4
$161M Buy
395,780
+57,855
+17% +$21.4M 0.14% 193
2023
Q3
$118M Buy
337,925
+26,290
+8% +$9.19M 0.11% 241
2023
Q2
$110M Buy
311,635
+8,617
+3% +$2.9M 0.1% 258
2023
Q1
$95.5M Buy
303,018
+1,917
+0.6% +$575K 0.09% 283
2022
Q4
$87M Buy
301,101
+35,292
+13% +$10.8M 0.09% 286
2022
Q3
$77M Sell
265,809
-134,151
-34% -$38.6M 0.08% 314
2022
Q2
$113M Buy
399,960
+157,191
+65% +$42.1M 0.11% 253
2022
Q1
$63.4M Sell
242,769
-42
-0% -$9.97K 0.05% 410
2021
Q4
$52.4M Sell
242,811
-43,385
-15% -$8.44M 0.04% 469
2021
Q3
$51.6M Sell
286,196
-123,143
-30% -$24M 0.05% 457
2021
Q2
$82.3M Buy
409,339
+20,324
+5% +$4.25M 0.07% 353
2021
Q1
$83.3M Sell
389,015
-3,587
-0.9% -$788K 0.08% 334
2020
Q4
$92.7M Sell
392,602
-45,197
-10% -$10.4M 0.1% 284
2020
Q3
$119M Buy
437,799
+14,507
+3% +$4M 0.14% 208
2020
Q2
$123M Buy
423,292
+38,240
+10% +$10.4M 0.15% 180
2020
Q1
$91.6M Buy
385,052
+5,352
+1% +$1.23M 0.14% 200
2019
Q4
$83.1M Buy
379,700
+6,350
+2% +$1.29M 0.1% 291
2019
Q3
$63.3M Buy
373,350
+13,157
+4% +$2.33M 0.08% 344
2019
Q2
$66.1M Buy
360,193
+11,863
+3% +$2.07M 0.08% 342
2019
Q1
$64.1M Buy
348,330
+92,287
+36% +$17M 0.08% 344
2018
Q4
$42.4M Buy
256,043
+6,951
+3% +$1.2M 0.06% 396
2018
Q3
$48M Buy
249,092
+657
+0.3% +$117K 0.05% 418
2018
Q2
$42.2M Buy
248,435
+3,696
+2% +$573K 0.05% 454
2018
Q1
$39.9M Buy
244,739
+19,985
+9% +$3.26M 0.05% 464
2017
Q4
$33.7M Buy
224,754
+1,277
+0.6% +$189K 0.04% 505
2017
Q3
$34M Sell
223,477
-17,510
-7% -$2.64M 0.04% 485
2017
Q2
$31.1M Sell
240,987
-5,344
-2% -$643K 0.04% 500
2017
Q1
$26.9M Buy
246,331
+12,060
+5% +$1.06M 0.03% 525
2016
Q4
$17.3M Sell
234,271
-343,963
-59% -$28M 0.02% 626
2016
Q3
$50.4M Sell
578,234
-56,654
-9% -$5.35M 0.07% 374
2016
Q2
$54.6M Buy
634,888
+95,740
+18% +$8.27M 0.08% 345
2016
Q1
$42.9M Sell
539,148
-1,453
-0.3% -$131K 0.06% 400
2015
Q4
$68M Buy
540,601
+28,747
+6% +$3.47M 0.09% 310
2015
Q3
$53.3M Buy
511,854
+34,159
+7% +$4.39M 0.07% 350
2015
Q2
$59M Buy
477,695
+50,367
+12% +$6.35M 0.07% 373
2015
Q1
$50.4M Buy
427,328
+129,119
+43% +$15.5M 0.05% 423
2014
Q4
$35.4M Buy
298,209
+249,358
+510% +$28.1M 0.04% 505
2014
Q3
$5.49M Sell
48,851
-2,375
-5% -$226K 0.01% 944
2014
Q2
$4.85M Sell
51,226
-1,725
-3% -$121K ﹤0.01% 980
2014
Q1
$3.74M Sell
52,951
-3,822
-7% -$303K ﹤0.01% 975
2013
Q4
$4.22M Sell
56,773
-1,060,728
-95% -$73.9M ﹤0.01% 924
2013
Q3
$84.7M Sell
1,117,501
-984,883
-47% -$78.4M 0.09% 311
2013
Q2
$168M Buy
+2,102,384
New +$155M 0.2% 154

Other funds holding VRTX

Neuberger Berman Group's VRTX Position: Q1 2026 in Review

Neuberger Berman Group increased its Vertex Pharmaceuticals (VRTX) stake by 1% in Q1 2026, buying an estimated $2.62M and bringing the position to 551,522 shares worth $246M. The position accounts for 0.19% of the portfolio, ranked #114.

Neuberger Berman Group first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $247M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Neuberger Berman Group held 551,522 shares of Vertex Pharmaceuticals worth $246M as of Q1 2026.
  • Neuberger Berman Group bought 5,625 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.62M.
  • Vertex Pharmaceuticals made up 0.19% of Neuberger Berman Group's portfolio in Q1 2026, its #114 holding.
  • Neuberger Berman Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Neuberger Berman Group's Vertex Pharmaceuticals position peaked at $247M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.